Carboxylates extrahepatic Gla proteins — matrix Gla protein (inhibits vascular calcification), osteocalcin (binds bone Ca²⁺), Gas6 (axon regeneration). Short (4-isoprenoid) side chain gives MK-4 a shorter plasma t½ (~1 h) than MK-7 but higher tissue turnover. Extrahepatically synthesised from K1 via side-chain conversion — dietary MK-4 supplements the tissue pool directly.
Half-Life & Elimination Curve (PO: 1h)
Plasma (PO)t½ Decay (1h)
0×t½0h100%(0.208 µg/L)
1×t½1h50%(0.104 µg/L)
2×t½2h25%(0.0519 µg/L)
3×t½3h12.5%(0.0259 µg/L)
4×t½4h6.3%(0.013 µg/L)
5×t½5h3.1%(0.00649 µg/L)
Elimination t½1h (PO)
Rate Constant (ke)0.693 h⁻¹
Time to Peak (Tmax)1.19h
Est. Peak (Cmax)0.208 µg/L
Clearance (CL)9.7 L/h
97% Washout (5×t½)5h
Dosing Guidelines
Oral (PO): Typical 133 mcg (Range: 100–200 mcg)
Pharmacokinetic Parameters
Oral (PO): Bioavailability (F): 5% · Volume of Distribution (Vd): 14 L · Absorption (ka): 1 h⁻¹ (t½ka ≈ 42m) [PMID 23140417]